Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.37 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541313 | 0.93 | PROKR1 (0.38) | HTR2CTRPC3TRPC6PROKR1PKM | |
| SCHEMBL3543877 | 0.90 | HTR2C (0.40) | HTR2CTRPC3TRPC6PKM | |
| SCHEMBL3537435 | 0.89 | PRKD3 (0.44) | HTR2CKMT2A | |
| SCHEMBL3538068 | 0.88 | CPT1A (0.41) | HTR2CTRPC3TRPC6KMT2AABL1 | |
| SCHEMBL3540045 | 0.87 | KDM4E (0.39) | GFERHTR2CKMT2A | |
| SCHEMBL3545073 | 0.86 | HTR2C (0.44) | GFERHTR2CKMT2A | |
| SCHEMBL3541503 | 0.86 | RAB9A (0.38) | HTR2CTRPC3TRPC6KMT2APROKR1 | |
| SCHEMBL3542690 | 0.85 | RAB9A (0.45) | HTR2CTRPC3TRPC6KMT2A | |
| SCHEMBL3538100 | 0.84 | KDM4E (0.38) | GFERHTR2CKMT2APDE4BPDE4D | |
| SCHEMBL3540903 | 0.84 | PROKR1 (0.41) | HTR2CKMT2APROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101370796-A | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | claimed |
| CN-101370796-B | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE | 2012-10-10 | — | — | CN | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-101370796-A | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | GFER 4067/4885HTR2C 422/4885TRPC3 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.